不是，有这个杂志
既然是杂志网，可信度当然需要怀疑还是亲自试验过的人来回答吧建议不要轻易相信！
中国血液净化杂志怎么投稿可以把你的稿写好以后经过专家帮你审核以后确实觉得挺好，然后往中国血液净化杂志上投稿。
中国血液净化杂志怎么投稿可以把你的稿写好以后经过专家帮你审核以后确实觉得挺好，然后往中国血液净化杂志上投稿。
刘惠兰教授1962年毕业于北京大学医学院医疗系。1986年在美国做访问学者。现任首都医科大学肾脏病学系副主任，北京市血液透析质量控制专家组成员，《中国血液净化》杂志编审。 曾任首都医科大学附属复兴医院肾内科主任、中华医学会北京肾病分会常委、北京生物医学工程学会血液净化组副主任委员、首都医科大学学术委员会委员。《中华内科杂志》编审、《首都医科大学学报》编委、《中国血液净化》杂志学术委员会委员、《中华中西医结合》杂志特邀编委。
如果想投稿中国血液净化杂志，你可以按照他的要求以及程序往他的邮箱里直接投。
不是，有这个杂志
中国血液净化杂志怎么投稿可以把你的稿写好以后经过专家帮你审核以后确实觉得挺好，然后往中国血液净化杂志上投稿。
不是，有这个杂志
既然是杂志网，可信度当然需要怀疑还是亲自试验过的人来回答吧建议不要轻易相信！
给人的感觉就是假的，但是看见这家网站是在百度做的推广啊，如果真是这样的话，百度也太不负责任了啊
《中国血液净化》杂志社是2002-01-07在北京市西城区注册成立的集体所有制，注册地址位于北京市西城区阜成门内大街133号。《中国血液净化》杂志社的统一社会信用代码/注册号是91110102733473841K，企业法人王梅，目前企业处于开业状态。《中国血液净化》杂志社的经营范围是：出版、发行《中国血液净化》杂志；承办《中国血液净化》杂志国内广告、发布外商来华广告；技术咨询、技术培训；承办展览展示；广告信息咨询；会议服务。（企业依法自主选择经营项目，开展经营活动；依法须经批准的项目，经相关部门批准后依批准的内容开展经营活动；不得从事本市产业政策禁止和限制类项目的经营活动。）。在北京市，相近经营范围的公司总注册资本为1111151万元，主要资本集中在 5000万以上 规模的企业中，共67家。通过爱企查查看《中国血液净化》杂志社更多信息和资讯。
既然是杂志网，可信度当然需要怀疑还是亲自试验过的人来回答吧建议不要轻易相信！
不是，有这个杂志
如果想投稿中国血液净化杂志，你可以按照他的要求以及程序往他的邮箱里直接投。
Blood purification pharmacokinetics Shanghai Jiaotong University College of Medicine subsidiary Ruijin Hospital kidney Chen Nan-J) N FWR; t Blood purification technology in clinical treatment of acute and chronic renal failure has been nearly half a century, and in critically ill patients, such as acute renal failure (ARF) in the treatment of continuous renal replacement therapy (CRRT) more traditional intermittent hemodialysis greater advantages, its clinical application is gradually expanded from the traditional kidney renal replacement to support development, participate in a multidisciplinary critical severe _ (HwU> Whether or ARF in patients with CRF usually kinds of medication, drugs in the application of these patients should be in accordance with its residual renal function adjustment, and at the same time, blood purification and changed the drug metabolism in patients with these conditions, particularly in critically ill patients, such as failure to consider this factor, medication adjustment programmes, the consequences could be Q: bKT # \ 1) from the following three aspects of the assessment of patients with blood purification P (rS - `I First, the nature of drug j1ZFsTFMWp 1, renal clearance in the proportion of drug: drug in the body's overall clearance rate is the body organ system capacity to remove the sum of drugs, including liver, kidney, as well as other metabolic If drugs mainly through kidney removal, which is usually to remove CRRT part of the in vitro clear / removal of the overall ≥ 25 ~ 30%, it is necessary to adjust the Pio ^ 5j hB6 2, protein binding rate: drug free with biological activity and can be removed filtration, plasma protein binding is the high rate of drugs (such as digitalis glycosides drug, warfarin, ) are difficult to remove CRRT Protein binding rate can be affected by many factors, the theoretical value and the actual situation may have some ! A! \ S / x4 3, molecular weight: small molecular diffusion easy to be adopted by dialysis membrane pore, drug removals and molecular size inversely proportional to macromolecules often convection through, unless more than its molecular weight film hole size, or ultrafiltration rate associated with the Most of the molecular weight of less than 500 drug Da, Da little more than Extension of high-flux dialysis membrane and time of removal can be improved 'T [zh # v> S 4, the volume of distribution (Vd): in vivo drug representatives of the extent of the Vd representative of the high rate of drug organizations with high clearance rate is Vd patients with severe and theoretical value can be very different, but there are individual Drug Vd ≤ 1 L / kg easy clearance, ≥ 2 L / kg difficult to be High flow could be higher IHD Vd drug rapidly cleared from plasma, serum concentration decreased, but only in a dialysis drug remove a small part in the two dialysis between plasma concentration will quickly CRRT continued slow clearance high Vd drugs, the process of drug plasma from the organizations to re-distribution, the change in the plasma concentration of ( 9X, Cefaclor 1 25 24-35 25-5 tid not adjusted to 25 sU? "V Cefoperazone 6-5 90 14-20 1-2 q12h thoroughly after delivery without adjustment?,: # 9 Cefuroxime 2 33 13-18 75-5 q8h thoroughly after administration 0 q12h * i? RJH Ceftazidime 2 17 28-4 1-0 q8h 0 1-0 q24-48h YxE bg (Y Amikacin 4-3 <5 22-29 5mg/kg q12h 2 / 3 of the normal 30-70% q12-18h wI! + L & Q Tobramycin 5 <5 22-33 7mg/kg q8h 2 / 3 of the normal 30-70% q12h lC = N: = Mu Ciprofloxacin 3-6 20-40 5 5-75 q12h 25 q12h 2 q12h, $ h (fM8GC Levofloxacin 4-8 24-38 1-5 5 q24h 25-50% 50% + T, H & # Imipenem 1 13-21 17-3 5-0 q6h thoroughly after administration 50 percent - J "qrp Z ^ Vancomycin 6-8 10-50 47-1 5 q6h 5 q48-q24-96h 5% 48h c X: 3 30 4 losartan 50mg qd-q12h unclear hundred percent jq57C)) X 2 Benazepril 22 95 15 10mg qd not 50-75% uw K h Monopril 12 95 15 10mg qd not 100% [T'yc: = Atenolol 7 45-60 5-10 50-100mg qd 25-50mg 50% q48h s ULIrYRA The name of the drug half-life F Ze: co8Mu (H) protein binding 0zw + @ l ` (%) Vd `" a? A 5] k (L / Kg) renal function f) * NX After the normal dose HD ^ fs m6 f)) SUPPLEMENTARY of CRRT j ~ Q) F | i8 Carvedilol 5-8 95 1-2 25-50mg q12-24h not 100 percent [6AHaOhR ' Nifedipine 4-5 97 4 10-20mg q6-8h not 100%> s & XX, w Amlodipine 35-50 95 21 5mg qd not 100 percent 1p8: 1) q Felodipine 10-14 99 9-10 10mg qd not 100% gs? 8Wzh90 * Digoxin 36-44 20-30 5-8 25-5mg qd not 25-75% q36h H4t) + (: D ' Low-molecular-weight heparin 2-0 unclear 06-13 30-40mg bid unclear 100% p "2m9 0IO Warfarin 34-35 99 15 load 10-15 mg of 2-10 mg qd not iHPUmTus not -- Azathioprine 16-1 20 55-8 5-5mg/kg q24h 25mg/kg 75% yq?] V7 ~ Cyclophosphamide 4-5 14-20 5-1 1-5mg/kg qd 1 / 2 dose of 100% Z:! IX ^ q;) n Vincristine 1-5 75 5-11 4mg / sq m unclear 100% I! P4 (3skAB Prednisone 5-5 80 2 5-60mg qd not 100% X x_ tpC? Prednisolone 5-5 80 2 5-60mg qd need 100 percent OZf6/10O / A prednisone 9-0 40-60 2-5 4-48mg qd not 100 percent [@ / /) # 5v Insulin 2-4 5 15 Indefinite not 75% `([R j M` Acarbose 3-9 15 32 50-200mg tid unclear avoid / 'ZKST4 Effects of Fluvastatin small 5-1 98 42 2-10mg qd unclear 100% k O1)? DWpa Simvastatin 2> 95 mg qd unclear 5-40 unclear 100%
核心。国家级。我这有，私聊